ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "biomarkers and rheumatoid arthritis (RA)"

  • Abstract Number: 1501 • 2018 ACR/ARHP Annual Meeting

    Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate

    Tate Johnson1, Bryant R. England2, Harlan Sayles1, Geoffrey M. Thiele1, Ted R. Mikuls3 and James R. O'Dell4, 1University of Nebraska Medical Center, Omaha, NE, 2Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, 3Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 4Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: The Multi-Biomarker Disease Activity (MBDA) score was developed to provide an objective measure of rheumatoid arthritis (RA) disease activity. Demonstrating moderate correlations with conventional…
  • Abstract Number: 2041 • 2018 ACR/ARHP Annual Meeting

    Serum Level of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1): A New Biomarker of Disease Activity in Rheumatoid Arthritis

    Clémence Gorlier1, Hafid Ait Oufella2, Ludivine Laurans2, Alexandra Rousseau3, Sophie Georgin-Lavialle4, Harry Sokol5, Francis Berenbaum1, Simon Tabassome6, Jacques-Eric Gottenberg7 and Jeremie Sellam1, 1AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, 2Inserm U970, Paris Cardiovascular Research Center, Paris, France, 3AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB, Paris, France, 4AP-HP Tenon hospital, Sorbonne Université Paris, Paris, France, 5AP-HP Saint-Antoine hospital, Sorbonne Université Paris, France, Paris, France, 6AP-HP Saint-Antoine Hospital, Plateforme de Recherche Clinique de l’Est Parisien (URCEST-CRCEST-CRB), Paris, France, 7Department of Rheumatology, Strasbourg University Hospital, Université de Strasbourg, CNRS, Strasbourg, France, Strasbourg, France

    Background/Purpose: Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is a cell surface receptor expressed mainly on monocytes and neutrophils, known to amplify inflammatory response. We…
  • Abstract Number: 564 • 2018 ACR/ARHP Annual Meeting

    Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)

    Katie Tuckwell1, Cem Gabay2, Thierry Sornasse1, Ruediger Laubender3, Jianmei Wang4 and Michael Townsend1, 1Genentech, Inc., South San Francisco, CA, 2University Hospitals of Geneva, Geneva, Switzerland, 3Roche Diagnostics, Penzberg, Germany, 4Roche Products Ltd., Welwyn Garden City, United Kingdom

    Background/Purpose: The biomarkers CXCL13 and sICAM1 have been associated with outcomes in patients with RA treated with TCZ. This study evaluated the association of CXCL13…
  • Abstract Number: 1474 • 2018 ACR/ARHP Annual Meeting

    Circulating Transfer RNA-Derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis

    Qiong Wu, Quanhu Sheng, Joseph F. Solus, Kasey Vickers, Ryan Allen, Shilin Zhao, Yan Guo, Fei Ye, C Michael Stein and Michelle J. Ormseth, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Small RNAs (sRNAs) are important gene regulators and markers of disease. Transfer RNA (tRNA)-derived sRNAs (tDRs), including tRNA fragments (tRFs) and halves (tRHs), are…
  • Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting

    Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia

    Malin C Erlandsson1,2, Minna Turkkila3, Rille Pullerits2,3,4 and Maria I Bokarewa2,3, 1Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, 2Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, 4Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden

    Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…
  • Abstract Number: 421 • 2017 ACR/ARHP Annual Meeting

    Serum Calprotectin Is Not Predictive for Successful Dose Reduction or Discontinuation of TNF Inhibitors in RA Patients with Low Disease Activity

    Nathan den Broeder1, Lieke Tweehuysen1, Noortje van Herwaarden1, Thomas Vogl2, F.H.J. van den Hoogen1, Rogier Thurlings3 and Alfons A Den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2University of Muenster, Muenster, Germany, 3Rheumatology, Radboudumc, Nijmegen, Netherlands

    Background/Purpose: Dose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1 To…
  • Abstract Number: 422 • 2017 ACR/ARHP Annual Meeting

    No Added Predictive Value of Serum Calprotectin for Treatment Response to Adalimumab or Etanercept in RA Patients

    Lieke Tweehuysen1, Nathan den Broeder1, Leo .A.B. Joosten2, Thomas Vogl3, F.H.J. van den Hoogen4, Rogier Thurlings5 and Alfons A Den Broeder1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, 3University of Muenster, Muenster, Germany, 4Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 5Rheumatology, Radboudumc, Nijmegen, Netherlands

    Background/Purpose: To date, no clinically useful baseline biomarkers have been found to predict response to TNF inhibitor (TNFi) treatment .1 Calprotectin was shown to be…
  • Abstract Number: 504 • 2017 ACR/ARHP Annual Meeting

    Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients

    Peter C. Taylor1, René Galien2, Annegret Van der Aa3, Corinne Jamoul3, Pille Harrison3, Chantal Tasset3, Yang Pan4, Lovely Goyal4, Wanying Li4 and Jacqueline Tarrant4, 1Kennedy Institute of Rheumatology, London, United Kingdom, 2Galapagos SASU, Romainville, France, 3Galapagos NV, Mechelen, Belgium, 4Gilead Sciences, Foster City, CA

    Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study (DARWIN 2) as monotherapy in active rheumatoid arthritis…
  • Abstract Number: 1355 • 2017 ACR/ARHP Annual Meeting

    14-3-3η:  Useful for More Than the Diagnosis of Rheumatoid Arthritis?

    Lisa Zickuhr1, Maryam Pourpaki2, Martha M. Brooks3 and Amy Joseph4, 1Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 2Rheumatology, Advocate Christ Medical Center at Chicago, Oak Lawn, IL, 3Rheumatology, St. Louis VA Medical Center, St. Louis, MO, 4Rheumatology, Veterans Administration Central Office, St. Louis, MO

    Background/Purpose: Chronic hepatitis C virus (HCV) infection can masquerade as rheumatoid arthritis (RA). Distinguishing between the two is important because treatments differ. 14-3-3η has been…
  • Abstract Number: 1371 • 2017 ACR/ARHP Annual Meeting

    Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage

    Jeffrey R. Curtis1, Darl D. Flake II2, Michael Weinblatt3, Nancy A. Shadick4, Mikkel Østergaard5, Merete Lund Hetland6, Cecilie Heegaard Brahe6, Yong Gil Hwang7, Daniel E. Furst8, Vibeke Strand9, Carol J. Etzel10, Dimitrios A. Pappas11, Xingbin Wang12, Ching Chang Hwang13, Eric H. Sasso12, Alexander Gutin2, Elena Hitraya12 and Jerry S. Lanchbury2, 1Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Myriad Genetics Inc., Salt Lake City, UT, 3Brigham and Women’s Hospital, Boston, MA, 4Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 6Copenhagen Center for Arthritis Research, Copenhagen, Denmark, 7Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8David Geffen School of Medicine at UCLA, Los Angeles, CA, 9Stanford University, Palo Alto, CA, 10Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, 11Columbia University, New York, NY, 12Crescendo Bioscience Inc., South San Francisco, CA, 13Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose: The MBDA score, based on 12 serum proteins, is a validated tool for assessing disease activity in RA patients. MBDA biomarkers may be influenced…
  • Abstract Number: 1377 • 2017 ACR/ARHP Annual Meeting

    The Serum Levels of Semaphorin 4D Are Associated with Disease Activity As Well As Radiographic Progression in Patients with Rheumatoid Arthritis

    Ji Hyoun Kim1, You-Jung Ha2, Sang Wan Chung3, Eun Ha Kang2, Yeong Wook Song4,5 and Yun Jong Lee6, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South), 3Department of Internal Medicine, Department of Internal Medicine, Sarang Hospital, Incheon, Korea, Republic of (South), 4Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), 5WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 6Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South)

    Background/Purpose: Progranulin (PGRN) and semaphorins (sema) are known to be involved in immune responses as well as bone remodeling process. The aim of this study…
  • Abstract Number: 1387 • 2017 ACR/ARHP Annual Meeting

    In-Depth Temperature of Small and Large Joints Assessed By Microwave Radiometry As an Additional Biomarker in Rheumatoid Arthritis

    Katerina Laskari1, George Pentazos1, George Konstantonis1, Ioannis Raftakis2, Elias Siores3 and Petros P Sfikakis1, 1Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, 2Rheumatology Department, Asklepion General Hospital, Athens, Greece, 3Institute of Materials Research and Innovation, University of Bolton, Bolton, United Kingdom

    Background/Purpose: Microwave Radiometry (MR) is an easy-to-perform, rapid, non-invasive, objective method, able to measure in-depth tissue temperature. In a proof-of-concept study using joint ultrasound as…
  • Abstract Number: 1458 • 2017 ACR/ARHP Annual Meeting

    Correlation of Multi-Biomarker Disease Activity Score with Clinical Disease Activity Measures for the JAK1-Selective Inhibitor Filgotinib As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients

    Mark C. Genovese1, René Galien2, Yang Pan3, Annegret Van der Aa4, Corinne Jamoul4, Pille Harrison4, Chantal Tasset4, Lovely Goyal3, Wanying Li3 and Jacqueline Tarrant3, 1Stanford University Medical Center, Palo Alto, CA, 2Galapagos SASU, Romainville, France, 3Gilead Sciences, Foster City, CA, 4Galapagos NV, Mechelen, Belgium

    Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) was efficacious as both add-on to methotrexate (MTX) and monotherapy in two 24-week phase 2B studies in…
  • Abstract Number: 1818 • 2017 ACR/ARHP Annual Meeting

    Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study

    S Bandyopadhyay1, MA Maldonado1, R Ammar1, Michael Schiff2, Michael Weinblatt3, Roy Fleischmann4 and SE Connolly1, 1Bristol-Myers Squibb, Princeton, NJ, 2University of Colorado, Denver, CO, 3Brigham and Women’s Hospital, Boston, MA, 4University of Texas Southwestern Medical Centre, Dallas, TX

    Background/Purpose: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models,…
  • Abstract Number: 1899 • 2017 ACR/ARHP Annual Meeting

    Osteopontin and Leptin Are Associated with Erosive Disease in an Inception Cohort of Rheumatoid Arthritis Treated-to-Target with Combination Conventional DMARD Therapy

    Mihir D. Wechalekar1,2,3, Susan Lester4, Sunil Nagpal5, Suzanne Cole6, Jessica Peters7, Anuk Das8, Pravin Hissaria9, Tania Crotti10, Catherine Hill1,11,12, Sudha Raghunath13, Llew Spargo14, Jennifer G Walker13,14,15, Malcolm D. Smith2 and Susanna Proudman1,10, 1Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, 2Flinders University, Adelaide, Australia, 3Rheumatology Unit, Repatriation General Hospital, Adelaide, Australia, 4Queen Elizabeth Hospital, Adelaide, Australia, 5Immunology, Janssen Research & Development, Spring House, PA, 6Immunology, Janssen Research and Development, Spring House, PA, 7Janssen Research & Development, Spring House, PA, 8Janssen R&D, Berwyn, PA, 9Immunology, SA Pathology, Adelaide, Australia, 10University of Adelaide, Adelaide, Australia, 11Medicine, The University of Adelaide, Adelaide, Australia, 12The Queen Elizabeth Hospital, Adelaide, Australia, 13Repatriation General Hospital, Adelaide, Australia, 14Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, 15Flinders University of South Australia, Adelaide, Australia

    Background/Purpose: We sought to identify biomarkers associated with erosive disease and bone loss in an inception rheumatoid arthritis (RA) cohort receiving treat-to-target combination DMARD therapy…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology